We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,357
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1551
Virtus Investment Partners
VRTS
$1.08B
| $3.06M | 0.01% |
25,160
+1,088
| +5% | +$121K |
|
1552
John B. Sanfilippo & Son
JBSS
$996M
| $3.06M | 0.01% |
33,536
+1,735
| +5% | +$168K |
|
|
LADR
1553
Ladder Capital
LADR
$1.2B
| $3.06M | 0.01% |
169,553
+7,444
| +5% | +$128K |
|
1554
Adeia
ADEA
$3.3B
| $3.06M | 0.01% |
624,331
+30,890
| +5% | +$164K |
|
1555
Innoviva
INVA
$1.51B
| $3.05M | 0.01% |
215,402
+9,529
| +5% | +$117K |
|
1556
Corcept Therapeutics
CORT
$12B
| $3.05M | 0.01% |
252,023
+19,240
| +8% | +$268K |
|
|
TRHC
1557
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $3.04M | 0.01% |
62,477
+4,140
| +7% | +$194K |
|
|
IBTX
1558
DELISTED
Independent Bank Group, Inc.
IBTX
| $3.04M | 0.01% |
54,771
+1,653
| +3% | +$91.8K |
|
1559
ProPetro Holding
PUMP
$1.35B
| $3.03M | 0.01% |
269,448
+17,635
| +7% | +$158K |
|
1560
Sonic Automotive
SAH
$2.74B
| $3.03M | 0.01% |
97,728
+4,132
| +4% | +$131K |
|
|
UNVR
1561
DELISTED
Univar Solutions Inc.
UNVR
| $3.03M | 0.01% |
124,887
+2,742
| +2% | +$62.1K |
|
1562
Chefs' Warehouse
CHEF
$4.43B
| $3.02M | 0.01% |
79,131
+5,406
| +7% | +$197K |
|
1563
Glaukos
GKOS
$10.1B
| $3M | 0.01% |
55,174
+6,666
| +14% | +$406K |
|
|
SAFE
1564
Safehold
SAFE
$1.15B
| $3M | 0.01% |
42,490
+1,929
| +5% | +$122K |
|
1565
Ambarella
AMBA
$3.59B
| $3M | 0.01% |
49,463
+2,303
| +5% | +$128K |
|
1566
Capitol Federal Financial
CFFN
$1.12B
| $3M | 0.01% |
218,139
+4,451
| +2% | +$62.7K |
|
1567
BlackLine
BL
$1.79B
| $2.99M | 0.01% |
58,055
+3,187
| +6% | +$159K |
|
1568
Insmed
INSM
$21.5B
| $2.99M | 0.01% |
125,209
+8,380
| +7% | +$170K |
|
1569
Mesa Laboratories
MLAB
$574M
| $2.99M | 0.01% |
11,980
+742
| +7% | +$174K |
|
1570
Penske Automotive Group
PAG
$14.2B
| $2.97M | 0.01% |
59,207
+67
| +0.1% | +$3.31K |
|
|
MFA
1571
MFA Financial
MFA
$920M
| $2.97M | 0.01% |
97,117
-731
| -0.7% | -$22.3K |
|
1572
Natera
NTRA
$39.3B
| $2.95M | ﹤0.01% |
87,545
+10,578
| +14% | +$390K |
|
1573
StoneX
SNEX
$9.2B
| $2.95M | ﹤0.01% |
305,527
+15,765
| +5% | +$130K |
|
1574
Orthofix Medical
OFIX
$421M
| $2.95M | ﹤0.01% |
63,799
+3,655
| +6% | +$172K |
|
1575
Triumph Financial Inc
TFIN
$1.87B
| $2.93M | ﹤0.01% |
77,096
+2,919
| +4% | +$101K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.